Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Pyoderma Gangrenosum
NCT05821374Phase 1Withdrawn
- Sponsor
- Dartmouth Health
- Start
- Apr 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in pyoderma gangrenosum (PG), sponsored by Dartmouth Health. Primary endpoints: Physician's Global Assessment at Day 115 and Ulcer Size at Day 115. Planned start Apr 2024; status: withdrawn.
02
Drugs
deucravacitinib
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT05821374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821374.